Maxime Dely: What if We Could Leukoreduce Without a Filter?
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared on LinkedIn:
”What if we could leukoreduce without a filter?
When we talk about leukoreduction, we immediately think of leukocyte filters — disposable devices able to remove over 99% of white blood cells.
But… not everyone has access to them.
In some countries, the cost of this technology remains a major barrier to transfusion safety.
Yet there’s a simple, effective, and affordable alternative: the hard spin.
In many developing countries, the first step in whole blood processing is a soft spin.
This yields two main components:
- a PRP (platelet-rich plasma),
- and an RCC (red cell concentrate).
The issue? Around 90% of the residual white blood cells end up in the RCC.
And these cells can cause febrile non-haemolytic transfusion reactions, allergic reactions, and can even impair red cell storage quality.
By performing a hard spin, we create an interface between plasma and red cells — the well-known buffy coat.
That’s where most white cells accumulate.
The result?
A significant reduction in the residual leukocytes within the red cell concentrate — sometimes divided by 2, from 90% to 50% or even lower, depending on the separation and centrifugation settings.
The hard spin isn’t a miracle solution, but it’s a crucial first step toward safer transfusion, especially where resources are limited.
Because sometimes, innovation simply means doing better with what we have.”
Stay updated with Hemostasis Today.
-
Aug 11, 2026, 13:53Steven Lubega: Why Are Healthy Newborns Born Poorly Equipped To Stop Bleeding?
-
Aug 11, 2026, 13:47Why Stroke Risk Changes During Pregnancy – International Journal of Stroke
-
Aug 11, 2026, 13:43Moyahabo Julius Rampya: Shaping the Future of Stroke Care in Africa
-
Aug 11, 2026, 13:34Brett Hoover: Plaque Burden May Be Key to Predicting MACE Risk
-
Aug 11, 2026, 11:47Rucha Patil: Strengthening Evidence-Based Haemophilia Care Across India
-
Aug 11, 2026, 11:38Maria Hadjidemetriou: The Patient Perspective in Thalassemia Care
-
Aug 11, 2026, 11:04Wolfgang Miesbach: The Critical Need for Tailored Dosing in VWD
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC